tbuckley/cabot-search huggingface dataset:
68Ga-FAPI-04 PET/CT in the Detection of Non–FDG-Avid Solid Pseudopapillary Neoplasm of the Pancreas
Authors: Wei Liu, Weidong Gong, Jiayu Zhang, Jiao Ma, Chunyin Zhang
Journal: Clinical Nuclear Medicine (2022)

Solid pseudopapillary neoplasm of the pancreas is a rare tumor. A 46-year-old woman presented with chest pain for 6 months. Chest CT revealed a large mass of the right mediastinum. Then, she underwent 18F-FDG and 68Ga-FAPI-04 PET/CT scans for staging. However, we accidentally found that a non-FDG focus nodule in the body of the pancreas with elevated FAPI activity. Finally, biopsy of the nodule in the body of the pancreas confirmed the diagnosis of solid pseudopapillary neoplasm.
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Authors: Xiao Han, Xiaoyong Tang, Hui Zhu, Dongyuan Zhu, Xiqin Zhang, Xiangjiao Meng, Ying Hua, Zhongtang Wang, Yan Zhang, Wei Huang, Linlin Wang, Shuanghu Yuan, Pinliang Zhang, Heyi Gong, Yulan Sun, Yingjie Zhang, Zengjun Liu, Xiaomeng Dong, Fei Gai, Zhan Huang, Changbin Zhu, Jun Guo, Zhehai Wang
Journal: Journal for ImmunoTherapy of Cancer (2022)

Objective Robust biomarker predicting efficacy of immunotherapy is limited. Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease progression. This study aims to investigate predictive role of ctDNA short-term dynamic change (6 weeks postimmunotherapy) in a single-arm, phase 2 trial of sintilimab plus docetaxel for previously treated advanced non-small cell lung cancer (NSCLC) patients. Methods A total of 33 patients with advanced NSCLC with disease progression during or after any first-line treatment were prospectively enrolled between 2019 and 2020. Patients received sintilimab (200 mg, day 1, every 3 weeks) plus docetaxel (75 mg/m 2 , day 3, every 3 weeks) for 4–6 cycles, followed by maintenance therapy with sintilimab (200 mg, day 1, every 3 weeks) until disease progression or unacceptable toxic effects. Blood samples were prospectively collected at baseline, and after 2 cycles of treatment (6 weeks post-treatment). All samples were subjected to targeted next-generation sequencing with a panel of 448 cancer-related genes. The landscape of high-frequency genomic profile of baseline and 6th week was described. Major molecular characteristics in preselected genes of interest associated with response to second-line chemoimmunotherapy were analyzed. The curative effects and prognosis of patients were evaluated. Results Patients with ctDNA clearance at 6th week had decreased tumor volume, while most patients with positive ctDNA at 6th-week experienced an increase in tumor volume. Positive 6th-week ctDNA was associated with significantly shorter progression-free survival (PFS) (91 vs NR days; p&lt;0.0001) and overall survival (47 vs 467 days; p =0.0039). Clearance of clonal mutations and none new clonal formation at 6th week were associated with longer PFS (mPFS 89 vs 266 days, p =0.003). ctDNA clearance at 6th week was an independent risk factor for progression or death (HR=100 (95% CI 4.10 to 2503.00), p=0.005). Conclusion ctDNA status and ctDNA mutation clearance putatively serve as predictive biomarkers for sintilimab combined with docetaxel chemotherapy in pretreated advanced NSCLC patients.
TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
Authors: Maria Perez-Penco, Stine Emilie Weis-Banke, Aimilia Schina, Majken Siersbæk, Mie Linder Hübbe, Mia Aaboe Jørgensen, Inés Lecoq, Lucia Lara de la Torre, Simone Kloch Bendtsen, Evelina Martinenaite, Morten Orebo Holmström, Daniel Hargbøl Madsen, Marco Donia, Niels Ødum, Lars Grøntved, Mads Hald Andersen
Journal: Journal for ImmunoTherapy of Cancer (2022)

Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor survival, making it the third and fourth leading cause of all cancer-related deaths in the USA and European Union, respectively. The tumor microenvironment (TME) in PDAC is highly immunosuppressive and desmoplastic, which could explain the limited therapeutic effect of immunotherapy in PDAC. One of the key molecules that contributes to immunosuppression and fibrosis is transforming growth factor-β (TGFβ). The aim of this study was to target the immunosuppressive and fibrotic TME in PDAC using a novel immune modulatory vaccine with TGFβ-derived peptides in a murine model of pancreatic cancer. C57BL/6 mice were subcutaneously inoculated with Pan02 PDAC cells. Mice were treated with TGFβ1-derived peptides (major histocompatibility complex (MHC)-I and MHC-II-restricted) adjuvanted with Montanide ISA 51VG. The presence of treatment-induced TGFβ-specific T cells was assessed by ELISpot (enzyme-linked immunospot). Changes in the immune infiltration and gene expression profile in tumor samples were characterized by flow cytometry, reverse transcription-quantitative PCR (RT-qPCR), and bulk RNA sequencing. Treatment with immunogenic TGFβ-derived peptides was safe and controlled tumor growth in Pan02 tumor-bearing mice. Enlargement of tumor-draining lymph nodes in vaccinated mice positively correlated to the control of tumor growth. Analysis of immune infiltration and gene expression in Pan02 tumors revealed that TGFβ-derived peptide vaccine increased the infiltration of CD8+ T cells and the intratumoral M1/M2 macrophage ratio, it increased the expression of genes involved in immune activation and immune response to tumors, and it reduced the expression of myofibroblast-like cancer-associated fibroblast (CAF)-related genes and genes encoding fibroblast-derived collagens. Finally, we confirmed that TGFβ-derived peptide vaccine actively modulated the TME, as the ability of T cells to proliferate was restored when exposed to tumor-conditioned media from vaccinated mice compared with media from untreated mice. This study demonstrates the antitumor activity of TGFβ-derived multipeptide vaccination in a murine tumor model of PDAC. The data suggest that the vaccine targets immunosuppression and fibrosis in the TME by polarizing the cellular composition towards a more pro-inflammatory phenotype. Our findings support the feasibility and potential of TGFβ-derived peptide vaccination as a novel immunotherapeutic approach to target immunosuppression in the TME.
Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages
Authors: Mingxuan Zhu, Liangliang Bai, Xiaoxia Liu, Shaoyong Peng, Yumo Xie, Hong Bai, Huichuan Yu, Xiaolin Wang, Ping Yuan, Rui Ma, Jinxin Lin, Linping Wu, Meijin Huang, Yingjie Li, Yanxin Luo
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Colony-stimulating factor 1 receptor (CSF1R), a classic tyrosine kinase receptor, has been identified as a proto-oncogene in multiple cancers. The CSF1/CSF1R axis is essential for the survival and differentiation of M2-phenotype tumor-associated macrophages (M2 TAMs). However, we found here that the CSF1R expression was abnormally down-regulated in colorectal cancer (CRC), and its biological functions and underlying mechanisms have become elusive in CRC progression. Methods The expression of class III receptor tyrosine kinases in CRC and normal intestinal mucosa was accessed using The Cancer Genome Atlas and Gene Expression Omnibus datasets and was further validated by our tested cohort. CSF1R was reconstructed in CRC cells to identify its biological functions in vitro and in vivo . We compared CSF1R expression and methylation differences between CRC cells and macrophages. Furthermore, a co-culture system was used to mimic a competitive mechanism between CSF1R-overexpressed CRC cells and M2-like macrophages. We utilized a CSF1R inhibitor PLX3397 to ablate M2 TAMs and evaluated its efficacy on CRC treatment in animal models. Results We found here that the CSF1R is silenced in CRC, and the reintroduced expression of the receptor in CRC cells can be cleaved by caspases and constrain tumor growth in vitro and in vivo , functioning as a tumor suppressor gene. We further identified CSF1R as a novel dependence receptor, which has the potential to act as either a tumor suppressor gene or an oncogene, depending on its activated state. In CRC tumors, CSF1R expression is enriched in TAMs, and its expression is associated with poor prognosis in patients ith CRC. In a co-culture system, CRC cells expressing CSF1R compete with M2-like macrophages for CSF1R ligands, resulting in a decrease in CSF1R activation and cell proliferation in macrophages. Blocking CSF1R by PLX3397 could deplete M2 TAMs and augments CD8 + T cell infiltration, effectively inhibiting tumor growth and metastasis and improving responses to chemotherapy and immunotherapy. Conclusion Our findings revealed that CSF1R is a novel identified dependence receptor silenced in CRC. The silence abalienates its ligands to stimulate CSF1R expressed on M2 TAMs, which is an appealing therapeutic target for M2 TAM depletion and CRC treatment.
Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma
Authors: Qiangda Chen, Hanlin Yin, Siyao Liu, Sami Shoucair, Ni Ding, Yuan Ji, Jicheng Zhang, Dansong Wang, Tiantao Kuang, Xuefeng Xu, Jun Yu, Wenchuan Wu, Ning Pu, Wenhui Lou
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background As an integral part of the tumor microenvironment (TME), tumor-associated neutrophils play a crucial role in tumor development. The objective of this study was to investigate the plasticity of tumor-associated N1 and N2 neutrophils in the TME of pancreatic ductal adenocarcinoma (PDAC), along with its impact on survival and association with immune infiltrations. Methods The primary and validation cohorts including 90 radical resection patients from September 2012 to May 2016 and 29 radical resection patients from September 2018 to October 2019, respectively, with complete survival data, were enrolled. Immunofluorescence staining was used to identify tumor-associated N1 and N2 neutrophils, and the N1/N2 ratio was used to evaluate N1 and N2 plasticity. Thereafter, the association between tumor-associated N1/N2 neutrophil plasticity, clinical features, and immune infiltrations was investigated. Results There was a significant increase in tumor-associated N2 neutrophils compared with tumor-associated N1 neutrophils. Low N1/N2 ratios were associated with the poorer differentiation of tumors, easier lymph node metastases, and a higher TNM stage. The median overall survival (OS) and recurrence-free survival (RFS) of the high tumor-associated N1 neutrophil group were significantly longer than those of the low group, while the tumor-associated N2 neutrophils played an opposite role. The multivariable analysis revealed that a high N1/N2 ratio was a significant prognostic indicator for OS and RFS. In addition, tumor-associated N1/N2 neutrophils showed an opposite correlation with tumor-infiltrating CD8 + T cells and Tregs. Conclusion The plasticity of tumor-associated N1/N2 neutrophils was identified as a crucial prognostic indicator that might reflect the TME and immune escape in patients with PDAC. On further investigation and validation, our findings may be used to further stratify patients with varying prognoses to optimize treatment.
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
Authors: Lunan Liu, Chao Ma, Zhuoyu Zhang, Matthew T Witkowski, Iannis Aifantis, Saba Ghassemi, Weiqiang Chen
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Adaptive CD19-targeted chimeric antigen receptor (CAR) T-cell transfer has become a promising treatment for leukemia. Although patient responses vary across different clinical trials, reliable methods to dissect and predict patient responses to novel therapies are currently lacking. Recently, the depiction of patient responses has been achieved using in silico computational models, with prediction application being limited. Methods We established a computational model of CAR T-cell therapy to recapitulate key cellular mechanisms and dynamics during treatment with responses of continuous remission (CR), non-response (NR), and CD19-positive (CD19 + ) and CD19-negative (CD19 − ) relapse. Real-time CAR T-cell and tumor burden data of 209 patients were collected from clinical studies and standardized with unified units in bone marrow. Parameter estimation was conducted using the stochastic approximation expectation maximization algorithm for nonlinear mixed-effect modeling. Results We revealed critical determinants related to patient responses at remission, resistance, and relapse. For CR, NR, and CD19 + relapse, the overall functionality of CAR T-cell led to various outcomes, whereas loss of the CD19 + antigen and the bystander killing effect of CAR T-cells may partly explain the progression of CD19 − relapse. Furthermore, we predicted patient responses by combining the peak and accumulated values of CAR T-cells or by inputting early-stage CAR T-cell dynamics. A clinical trial simulation using virtual patient cohorts generated based on real clinical patient datasets was conducted to further validate the prediction. Conclusions Our model dissected the mechanism behind distinct responses of leukemia to CAR T-cell therapy. This patient-based computational immuno-oncology model can predict late responses and may be informative in clinical treatment and management.
How Much of an “Advantage” Is Medicare Advantage?
Authors: David J. Meyers, Andrew M. Ryan, Amal N. Trivedi
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
390P Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Authors: H. Murakami, Y. Ohe, H. Hayashi, T. Esaki, T. Yamaguchi, T. Fukuhara, H. Daga, H. Tanaka, T. Kozuki, S. Osborne, W. Bordogna, K. Goto
Journal: Annals of Oncology (2022)
384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
Authors: H. Akamatsu, J.C-H. Yang, K. Wakuda, J. Hawkins, R.E. Yanes, O. Homann, M. Tan, E. Finger, H. Borghaei
Journal: Annals of Oncology (2022)
313P A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Authors: Y. Yu, W. Dong, Y. Shi, R. Wu, Q. Yu, F. Ye, C. Zhou, X. Dong, X. Li, Y. Li, Z. Li, Y. Pan, H. Shen, D. Wu, Z. Xu, J. Wu, N. Xu, Y. Qin, J. Li, S. Lu
Journal: Annals of Oncology (2022)
428P Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Authors: P. Sirohiya, H.K. Raju Sagiraju, M. Baruah, R. Singh, A. Elavarasi, S. Vig, B.K. Ratre, B. Kumar, A. Pandit, S. Bhatnagar
Journal: Annals of Oncology (2022)
332P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort
Authors: W. Fang, Y. Yang, Y. Zhao, Y. Huang, H. Zhao, N. Zhou, Y. Zhang, L. Chen, T. Zhou, G. Chen, T. Wu, L. Lu, S. Xue, L. Zhang
Journal: Annals of Oncology (2022)
436P Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Authors: A. Gulia, A. Puri, N. Kamath, R. Thakur, S. Laskar, J. Bajpai, N. Khanna, G. Chinnaswamy, B. Rekhi
Journal: Annals of Oncology (2022)
215P Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Authors: A. Mudgal, A.K. Vaid, M.K. Sahoo, J. Wadhwa, N. Sood, D. Gautam
Journal: Annals of Oncology (2022)
212P Dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplant for acute leukemias and myelodysplastic syndrome
Authors: D.H. Kim, Y. Park, D-Y. Shin, Y. Koh, J.M. Byun, J. Hong
Journal: Annals of Oncology (2022)
286P Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
Authors: A. Body, E.S. Ahern, L. Lal, H. Abdulla, S. Opat, P. Downie, M. Leahy, N. Fuentes-Bolanos, B. Padhye, N. Hamad, V. Milch, E. Segelov
Journal: Annals of Oncology (2022)
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience
Authors: J. Bajpai, V. Simha, S. Anne, P.G. Bhargava, S. Srinivas, N. Khanna, B. Rekhi, V. Noronha, V.M. Patil, S. Laskar, K. Prabhash, S. Gupta, S. Banavali
Journal: Annals of Oncology (2022)
308P Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Authors: M. Nakashima, S. Tanzawa, H. Tanaka, M. Inaba, J. Nakamura, K. Shibata, T. Kishikawa, K. Fujiwara, T. Kohyama, H. Ishida, T. Misumi, K. Shiraishi, N. Matsutani, N. Seki
Journal: Annals of Oncology (2022)
296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Authors: Y-L. Wu, M. Tsuboi, C. Grohe, T. John, M. Majem Tarruella, J. Wang, T. Kato, J.W. Goldman, S-W. Kim, C-J. Yu, H. Vinh Vu, G. Mukhametshina, C. Akewanlop, F. de Marinis, F.A. Shepherd, D. Urban, M. Stachowiak, A. Bolanos, X. Huang, R.S. Herbst
Journal: Annals of Oncology (2022)
302P Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study
Authors: J-Y. Shih, S.H. Lin, S. Nagar, M. Jimenez, K. Davis, D. Kahangire, L. Servidio, L. Ho, R. Veluswamy
Journal: Annals of Oncology (2022)
173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Authors: F. Parnis, B. Tombal, M. Hussain, F. Saad, K. Fizazi, C.N. Sternberg, E.D. Crawford, E. Kopyltsov, A. Rezazadeh Kalebasty, B.Y. Alekseev, A. Montesa Pino, D. Ye, F.J.S. Melo Cruz, T. Tammela, H. Suzuki, H. Joensuu, S. Thiele, R. Li, I. Kuss, M. Smith
Journal: Annals of Oncology (2022)
325P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort
Authors: Y. Huang, W. Fang, Y. Yang, Y. Zhao, H. Zhao, N. Zhou, Y. Zhang, L. Chen, T. Zhou, G. Chen, T. Wu, L. Lu, S. Xue, L. Zhang
Journal: Annals of Oncology (2022)
405P Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Authors: R. Soo, L. Mery, A. Bardot, R. Kanesvaran, T. Keong, D. Pongnikorn, N. Prasongsook, S. Hutajulu, C. Irawan, A. Ab Manan, M. Thiagarajan, P. Sripan, S. Peters, H. Storm, F. Bray, R. Stahel
Journal: Annals of Oncology (2022)
391P Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Authors: G.S. Panda, V. Noronha, V.M. Patil, A.P. Joshi, N.S. Menon, A.C. Singh, R. Kumar, T. Pai, O. Shetty, A. Janu, N. Chakrabarty, N. Purandare, S. Dey, K. Prabhash
Journal: Annals of Oncology (2022)
372P Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany
Authors: F. Griesinger, S. Popat, P. Okhuoya, L. Servidio, M.J. Fonseca, E. Tolani, S. Lu, S. Zacharias
Journal: Annals of Oncology (2022)
464TiP Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Authors: A.C.J. van Akkooi, A. Hauschild, G.V. Long, M. Mandala, M. Kicinski, A-S. Govaerts, I. Klauck, M. Ouali, P. Lorigan, A.M.M. Eggermont
Journal: Annals of Oncology (2022)
375P Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study
Authors: J.Y. Chen, H. Zhang, B.Y. Wang, J.M. Wen, X.Y. Xu, H.T. Li, M. Fan
Journal: Annals of Oncology (2022)
144P Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Authors: T. Hayase, S. Washino, S. Shirotake, M. Inoue, M. Kagawa, H. Takeshita, Y. Miura, Y. Hyodo, K. Izumi, S. Kawakami, K. Saito, Y. Kageyama, M. Oyama, T. Miyagawa
Journal: Annals of Oncology (2022)
382P Real-world data on treatment outcome of ALK positive non-small cell lung cancer from an Indian multi-centric cancer registry
Authors: S.S. Panda, L. Moharana, G. Biswas, P.K. Parida, S.K. Mishra, J. Pattnaik, S.P. Devaraj, S. Mohanty, S. Karunanidhi, S.L. Singuluri, S.V. Saju, A. Sehrawat, S. Mudgal, G.C. Subudhi, K.K. Rathnam, S.L. Cyriac, A.O. Philips, A.T. Jose, P. Ganesan
Journal: Annals of Oncology (2022)
LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis
Authors: S. Qin, Y. Guo, Z. Meng, J. Wu, K. Gu, T. Zhang, X. Lin, H. Lin, J-E. Ying, F. Zhou, K. Hsing-Tao, Y. Chao, S. Li, Y. Chen, F. Boisserie, R. Abdrashitov, Y. Bai
Journal: Annals of Oncology (2022)
338P Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Authors: J. Wei, A. Yuile, V. Khou, M. Itchins, B. Kong, N. Pavlakis, D.L. Chan, S. Clarke
Journal: Annals of Oncology (2022)
232MO Transcriptomic and tumor microenvironment landscape of EBV related nasopharyngeal carcinoma in endemic and non-endemic areas
Authors: L.F. Licitra, M. Serafini, F. Pistore, S. Canevari, C. Resteghini, S. Cavalieri, A. Trama, L. De Cecco
Journal: Annals of Oncology (2022)
62P Chief complaints and baseline clinicopathological features of patients with colorectal cancer in a tertiary hospital in Yogyakarta Indonesia
Authors: Y.R. Putra, S.H. Hutajulu, S. Susanti, D.S. Heriyanto, N. Yoshuantari, A. Handaya, B. Purwanto, M.S. Hardianti, K.W. Taroeno Hariadi, I. Purwanto, J. Kurnianda, M. Ilyas
Journal: Annals of Oncology (2022)
79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Authors: A. Vogel, S.L. Chan, J. Furuse, W.Y. Tak, G. Masi, M. Varela, J.H. Kim, S. Tanasanvimon, M.E. Reig Monzon, F. Dayyani, M. Makowsky, M. Marcovitz, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2022)